Hints and tips:
Related Special Reports
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...One of the “big five” academic publishers alongside Elsevier, SAGE, Springer Nature and Taylor & Francis, Wiley’s research publishing division reported revenues of $659mn in the nine months to January 31...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...Over a career spanning more than 70 years — most of which spent alongside the Sage of Omaha — Munger became famous for his sharp wit about investing and life delivered during Berkshire’s annual shareholders...
...The Sage of Omaha, Warren Buffett, sold off some of Berkshire Hathaway’s Chevron holdings in 2023 and some analysts have soured on the stock....
...molnupiravir or Paxlovid will [still] be effective, now that most people have been either vaccinated or infected,” said Andy Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics...
...to rescue Farfetch Regulators even out the antitrust score Global regulators had been on a losing streak lately, with back-to-back losses including Amgen’s $28bn takeover of fellow drugmaker Horizon Therapeutics...
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
...The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to...
...Andrew Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics department, said the drug also had potential side effects for pregnant women....
...Massachusetts-based Luminopia, which creates therapeutic visual stimuli, raised $16mn in late June....
...regulators have warned that “rampant consolidation” in the pharmaceuticals industry is pushing up prices for patients as the Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics...
...Amgen has reached an agreement with the US antitrust regulator that allows the drugmaker to press ahead with its $28bn acquisition of Horizon Therapeutics....
...Khan has become such an antagonist for dealmakers and why they were rejoicing this month when Amgen reached a settlement with her agency, allowing the pharmaceutical company’s $28bn acquisition of Horizon Therapeutics...
...The Federal Trade Commission sued to block the biotechnology company Amgen’s $28.3bn deal to acquire Horizon Therapeutics, Italy is struggling to spend €200bn in EU Covid recovery funds, and Ukraine said...
...His comments came after the US Federal Trade Commission on Tuesday sued to block Amgen’s $28bn takeover of Horizon Therapeutics....
...In December, biopharmaceutical firm Amgen announced the acquisition of biotech star Horizon Therapeutics for $116.50 per share or $28bn in aggregate....
...Herbs to improve memory and mood, such as sage and peppermint, grow as part of the installation, with recipes for tinctures....
...Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets...
...Amgen has agreed to buy Horizon Therapeutics for $28.3bn, including debt, after the California-based biotech won a three-way race to secure a new pipeline of drugs for rare autoimmune and inflammatory diseases...
...Late last year, Amgen bought Horizon Therapeutics for $28bn. Biotech and life science valuations have moderated since 2021. But the chance for premium buyouts has not disappeared....
...The FTC attempted to block Amgen’s $28.3bn takeover of Horizon Therapeutics. Barriers to M&A are going to make it harder for pharma companies to replenish drug pipelines....
...US Department of Justice, intend to follow through on their mission to draw a tougher line on antitrust.Still outstanding are large contested deals, including Amgen’s planned $28bn takeover of Horizon Therapeutics...
...When a sage like Buffett stakes his fortune, it is worth paying attention to the circumstances that would make his bet pay off. mark.vandevelde@ft.com...
International Edition